Where Things Stand on Medications for Cannabis Use Disorder
No medications are currently approved for cannabis use disorder, but several repurposed drugs and novel compounds targeting the endocannabinoid system show early promise.
Quick Facts
What This Study Found
The pharmacologic treatment of CUD remains in its early stages with no FDA-approved options. Gabapentin, N-acetylcysteine, synthetic cannabinoids, FAAH inhibitors, orexin receptor antagonists, and psychedelics are all being explored. Most show modest efficacy at best, and progress depends on better integration with behavioral treatments.
Key Numbers
No approved medications exist for CUD. Agents under investigation include gabapentin, N-acetylcysteine, synthetic cannabinoids, FAAH inhibitors, orexin receptor antagonists, and psychedelics. Most have shown only modest efficacy in trials to date.
How They Did This
Narrative review of PubMed, Google Scholar, and clinical trial registries from 2000 to 2025, focusing on human studies, randomized trials, and meta-analyses related to CUD pharmacotherapy.
Why This Research Matters
As cannabis legalization expands and CUD prevalence grows, the lack of effective medications represents a significant treatment gap. Understanding which compounds are in the pipeline helps frame realistic expectations.
The Bigger Picture
CUD treatment lags far behind alcohol and opioid use disorder in terms of pharmacological options. The shift toward targeting endocannabinoid tone and motivational circuits rather than just withdrawal symptoms represents a conceptual advance.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. Most referenced trials have small sample sizes. The field is evolving rapidly, so some findings may already be outdated.
Questions This Raises
- ?Will FAAH inhibitors or orexin antagonists prove effective in larger trials?
- ?Can stratifying patients by clinical phenotype improve treatment matching?
Trust & Context
- Key Stat:
- 0 FDA-approved medications for cannabis use disorder
- Evidence Grade:
- Moderate: comprehensive narrative review of current evidence, but limited by lack of systematic methodology and early-stage nature of most trials
- Study Age:
- Published in 2025 reviewing literature from 2000-2025
- Original Title:
- Emerging pharmacological strategies for the treatment of cannabis use disorder.
- Published In:
- Expert opinion on pharmacotherapy, 26(13), 1373-1377 (2025)
- Authors:
- Bahji, Anees(5)
- Database ID:
- RTHC-05997
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Are there any medications for cannabis addiction?
No medications are currently FDA-approved for cannabis use disorder. Several drugs are being tested, including gabapentin, N-acetylcysteine, and novel compounds targeting the endocannabinoid system, but none have shown strong enough results to earn approval yet.
What approaches look most promising?
Compounds targeting endocannabinoid tone (like FAAH inhibitors) and motivational circuits (like orexin antagonists) represent newer approaches that go beyond managing withdrawal symptoms. However, all are still in early research stages.
Read More on RethinkTHC
- 30-days-without-weed
- 6-months-sober-weed-what-to-expect
- 90-days-no-weed
- benefits-of-quitting-weed
- boredom-after-quitting-weed
- boredom-after-quitting-weed-nothing-fun
- cannabis-dependence-physical-psychological-addiction-science
- cannabis-perception-vs-evidence-gap
- cannabis-use-disorder-test
- creativity-without-weed-quitting-artist-musician
- cross-addiction-quit-weed-start-drinking
- hobbies-after-quitting-weed
- identity-after-quitting-weed
- is-weed-addictive
- is-weed-addictive-science
- leaving-stoner-culture-identity
- money-saved-quitting-weed-calculator
- one-year-sober-weed
- quitting-weed-and-alcohol
- quitting-weed-creativity
- quitting-weed-face-changes-skin
- quitting-weed-weight-loss-gain
- rehab-for-weed-addiction-necessary
- signs-of-cannabis-use-disorder
- weed-vape-pen-addiction
Cite This Study
https://rethinkthc.com/research/RTHC-05997APA
Bahji, Anees. (2025). Emerging pharmacological strategies for the treatment of cannabis use disorder.. Expert opinion on pharmacotherapy, 26(13), 1373-1377. https://doi.org/10.1080/14656566.2025.2558999
MLA
Bahji, Anees. "Emerging pharmacological strategies for the treatment of cannabis use disorder.." Expert opinion on pharmacotherapy, 2025. https://doi.org/10.1080/14656566.2025.2558999
RethinkTHC
RethinkTHC Research Database. "Emerging pharmacological strategies for the treatment of can..." RTHC-05997. Retrieved from https://rethinkthc.com/research/bahji-2025-emerging-pharmacological-strategies-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.